Seqens Seqens

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"MediPharm Labs","sponsor":"European Pharmaceutical","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"European Pharmaceutical Company STADA and MediPharm Labs Begin First Sales in Germany Under Exclusive Agreement","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"CANADA","productType":"Small molecule","productStatus":"Approved","date":"April 2021","url1":"","url2":"","graph1":"Neurology","graph2":"Approved"},{"orgOrder":0,"company":"MediPharm Labs","sponsor":"McMaster University","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Insomnia Treatment Study using MediPharm Labs CBD50 Product to Proceed to Phase 2 with Health Canada Consent","therapeuticArea":"Sleep","highestDevelopmentStatus":"Phase II","country":"CANADA","productType":"Small molecule","productStatus":"Approved","date":"August 2021","url1":"","url2":"","graph1":"Sleep","graph2":"Phase II"},{"orgOrder":0,"company":"MediPharm Labs","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MediPharm Labs Continues to Lead with Innovation - Launches CBG and Water-Soluble Products","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"CANADA","productType":"Small molecule","productStatus":"Approved","date":"April 2022","url1":"","url2":"","graph1":"Neurology","graph2":"Approved"},{"orgOrder":0,"company":"MediPharm Labs","sponsor":"Canntab Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Canntab and Medipharm Labs Enter Into a Wholesale Tablet Purchase Agreement","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Approved","country":"CANADA","productType":"Small molecule","productStatus":"Approved","date":"June 2020","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved"},{"orgOrder":0,"company":"MediPharm Labs","sponsor":"McMaster University","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"MediPharm Labs Enters Research Agreement with McMaster University to Develop Drugs Containing Cannabis Candidates","therapeuticArea":"Sleep","highestDevelopmentStatus":"Phase II","country":"CANADA","productType":"Small molecule","productStatus":"Approved","date":"June 2021","url1":"","url2":"","graph1":"Sleep","graph2":"Phase II"},{"orgOrder":0,"company":"MediPharm Labs","sponsor":"STADA Arzneimittel","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"European Pharmaceutical Company STADA and MediPharm Labs Begin First Sales in Germany Under Exclusive Agreement","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Approved","country":"CANADA","productType":"Small molecule","productStatus":"Approved","date":"April 2021","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Approved"},{"orgOrder":0,"company":"MediPharm Labs","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MediPharm Labs Continues to Lead with Innovation - Launches CBG and Water-Soluble Products","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"CANADA","productType":"Small molecule","productStatus":"Approved","date":"April 2022","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved"},{"orgOrder":0,"company":"MediPharm Labs","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","amount":"$16.0 million","upfrontCash":"Undisclosed","newsHeadline":"MediPharm Labs Enters Cannabis Research Agreement with Keck School of Medicine of USC","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"CANADA","productType":"Small molecule","productStatus":"Approved","date":"August 2022","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I"},{"orgOrder":0,"company":"MediPharm Labs","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MediPharm Labs Provides Update on Clinical Trial Progress Including FDA Approval of Partner Study","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"CANADA","productType":"Small molecule","productStatus":"Approved","date":"March 2023","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II"},{"orgOrder":0,"company":"MediPharm Labs","sponsor":"Avicanna","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Avicanna and Medipharm Labs Expand Strategic Manufacturing Agreement for Avicanna\u2019s Proprietary SEDDS Technology Capsules for Canadian and International Markets","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"CANADA","productType":"Small molecule","productStatus":"Approved","date":"June 2023","url1":"","url2":"","graph1":"Neurology","graph2":"Approved"},{"orgOrder":0,"company":"MediPharm Labs","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MediPharm Labs Publishes Study Investigating Medical Cannabis Impacts on Anxiety and Depression Outcomes in Fibromyalgia Patients","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase I","country":"CANADA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2023","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I"},{"orgOrder":0,"company":"MediPharm Labs","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MediPharm Labs Provides Update on Clinical Trial Progress Including FDA Approval of Partner Study","therapeuticArea":"Neurology","highestDevelopmentStatus":"IND Enabling","country":"CANADA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2023","url1":"","url2":"","graph1":"Neurology","graph2":"IND Enabling"},{"orgOrder":0,"company":"MediPharm Labs","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MediPharm Labs Launches New GMP Products to the Australian Medical Cannabis Market","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"CANADA","productType":"Small molecule","productStatus":"Approved","date":"September 2023","url1":"","url2":"","graph1":"Neurology","graph2":"Approved"},{"orgOrder":0,"company":"MediPharm Labs","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MediPharm Labs Launches New GMP Products to the Australian Medical Cannabis Market","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Approved","country":"CANADA","productType":"Small molecule","productStatus":"Approved","date":"September 2023","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved"}]

    Find Clinical Drug Pipeline Developments & Deals by MediPharm Labs

    Menu

    MediPharm Labs

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    APIs // Active Pharmaceutical Ingredients

    DEVELOPMENTS

    Key Products KEY PRODUCTS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              MediPharm Labs

              Contact Supplier
              • Development Update
              Virtual BoothMedipharm is a full-service pharmaceutical company delivering high-quality, innovative Cannabis concentrate-based products & services.
              Contact Supplier Contact Supplier
              Flag Canada
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              MediPharm Labs Launches New GMP Products to the Australian Medical Cannabis Market

              Details:

              Cannabis stimulates two receptors, cannabinoid receptor type 1 (CB1) and type 2 (CB2), within the endocannabinoid system. It is being investigated for multiple indications like post-surgical pain, depressive disorders, chronic headaches, alzheimer's agitation disorder, etc.

              Lead Product(s): Tetrahydrocannabinol

              Therapeutic Area: Neurology Product Name: Pink Kush

              Highest Development Status: Approved Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable September 27, 2023

              Medipharm CB

              ICRI Spring Convention

              Not Confirmed

              envelop Contact Supplier

              MediPharm Labs

              Contact Supplier
              • Development Update
              Virtual BoothMedipharm is a full-service pharmaceutical company delivering high-quality, innovative Cannabis concentrate-based products & services.
              Contact Supplier Contact Supplier
              Flag Canada
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              MediPharm Labs Launches New GMP Products to the Australian Medical Cannabis Market

              Details:

              Pink Kush (delta-9 tetrahydrocannabinol) is a CB2/CB1 receptor partial agonist, which is approved in combination with Cannabigerol for the treatment of stress, pain and depression.

              Lead Product(s): Tetrahydrocannabinol,Cannabigerol

              Therapeutic Area: Psychiatry/Psychology Product Name: Pink Kush

              Highest Development Status: Approved Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable September 27, 2023

              Medipharm CB

              ICRI Spring Convention

              Not Confirmed

              envelop Contact Supplier

              MediPharm Labs

              Contact Supplier
              • Development Update
              Virtual BoothMedipharm is a full-service pharmaceutical company delivering high-quality, innovative Cannabis concentrate-based products & services.
              Contact Supplier Contact Supplier
              Flag Canada
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              MediPharm Labs Publishes Study Investigating Medical Cannabis Impacts on Anxiety and Depression Outcomes in Fibromyalgia Patients

              Details:

              Cannabis stimulates two receptors, cannabinoid receptor type 1 (CB1) and type 2 (CB2), within the endocannabinoid system. It is being investigated for multiple indications like post-surgical pain, depressive disorders, chronic headaches, alzheimer's agitation disorder, etc.

              Lead Product(s): Cannabis-derived Therapy

              Therapeutic Area: Psychiatry/Psychology Product Name: Undisclosed

              Highest Development Status: Phase I Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable August 31, 2023

              Medipharm CB

              ICRI Spring Convention

              Not Confirmed

              envelop Contact Supplier

              MediPharm Labs

              Contact Supplier
              • Deals
              Virtual BoothMedipharm is a full-service pharmaceutical company delivering high-quality, innovative Cannabis concentrate-based products & services.
              Contact Supplier Contact Supplier
              Flag Canada
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Avicanna and Medipharm Labs Expand Strategic Manufacturing Agreement for Avicanna’s Proprietary SEDDS Technology Capsules for Canadian and International Markets

              Details:

              Under the agreement, Avicanna and Medipharm intend to commercialize various formulations of Avicanna’s proprietary cannabinoid-based Self-Emulsifying Drug Delivery Systems (SEDDS) technology capsules for the Canadian and international markets.

              Lead Product(s): Cannabidiol

              Therapeutic Area: Neurology Product Name: Undisclosed

              Highest Development Status: Approved Product Type: Small molecule

              Recipient: Avicanna

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Agreement June 26, 2023

              Medipharm CB

              ICRI Spring Convention

              Not Confirmed

              envelop Contact Supplier

              MediPharm Labs

              Contact Supplier
              • Development Update
              Virtual BoothMedipharm is a full-service pharmaceutical company delivering high-quality, innovative Cannabis concentrate-based products & services.
              Contact Supplier Contact Supplier
              Flag Canada
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              MediPharm Labs Provides Update on Clinical Trial Progress Including FDA Approval of Partner Study

              Details:

              Cannabis stimulates two receptors, cannabinoid receptor type 1 (CB1) and type 2 (CB2), within the endocannabinoid system. It is being investigated for multiple indications like post-surgical pain, depressive disorders, chronic headaches, alzheimer's agitation disorder, etc.

              Lead Product(s): Cannabidiol

              Therapeutic Area: Neurology Product Name: Undisclosed

              Highest Development Status: Phase II Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable March 01, 2023

              Medipharm CB

              ICRI Spring Convention

              Not Confirmed

              envelop Contact Supplier

              MediPharm Labs

              Contact Supplier
              • Development Update
              Virtual BoothMedipharm is a full-service pharmaceutical company delivering high-quality, innovative Cannabis concentrate-based products & services.
              Contact Supplier Contact Supplier
              Flag Canada
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              MediPharm Labs Provides Update on Clinical Trial Progress Including FDA Approval of Partner Study

              Details:

              Cannabis stimulates two receptors, cannabinoid receptor type 1 (CB1) and type 2 (CB2), within the endocannabinoid system. It is being investigated for multiple indications like post-surgical pain, depressive disorders, chronic headaches, alzheimer's agitation disorder, etc.

              Lead Product(s): Cannabis-derived Therapy

              Therapeutic Area: Neurology Product Name: Undisclosed

              Highest Development Status: IND Enabling Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable March 01, 2023

              Medipharm CB

              ICRI Spring Convention

              Not Confirmed

              envelop Contact Supplier

              MediPharm Labs

              Contact Supplier
              • Deals
              Virtual BoothMedipharm is a full-service pharmaceutical company delivering high-quality, innovative Cannabis concentrate-based products & services.
              Contact Supplier Contact Supplier
              Flag Canada
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              MediPharm Labs Enters Cannabis Research Agreement with Keck School of Medicine of USC

              Details:

              MediPharmto design, manufacture and supply a liquid oral cannabis study drug for the Phase 2 Life’s end Benefits of cannabidiol and tetrahydrocannabinol (LiBBY) study, to be conducted in the U.S., across 20 sites, to treat hospice-eligible patients diagnosed with dementia and agitation.

              Lead Product(s): Cannabidiol,Tetrahydrocannabinol

              Therapeutic Area: Neurology Product Name: T2:C100

              Highest Development Status: Phase I Product Type: Small molecule

              Partner/Sponsor/Collaborator: National Institutes of Health

              Deal Size: $16.0 million Upfront Cash: Undisclosed

              Deal Type: Funding August 09, 2022

              Medipharm CB

              ICRI Spring Convention

              Not Confirmed

              envelop Contact Supplier

              MediPharm Labs

              Contact Supplier
              • Development Update
              Virtual BoothMedipharm is a full-service pharmaceutical company delivering high-quality, innovative Cannabis concentrate-based products & services.
              Contact Supplier Contact Supplier
              Flag Canada
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              MediPharm Labs Continues to Lead with Innovation - Launches CBG and Water-Soluble Products

              Details:

              New CBG products include Advanced Formula, which is a CBG:CBD 1:2 oil, and Northbound, which is a high CBG vape cartridge with CBD inspired by The White and Appalachia strains.

              Lead Product(s): Cannabigerol,Cannabidiol

              Therapeutic Area: Neurology Product Name: CBG:CBD

              Highest Development Status: Approved Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable April 05, 2022

              Medipharm CB

              ICRI Spring Convention

              Not Confirmed

              envelop Contact Supplier

              MediPharm Labs

              Contact Supplier
              • Development Update
              Virtual BoothMedipharm is a full-service pharmaceutical company delivering high-quality, innovative Cannabis concentrate-based products & services.
              Contact Supplier Contact Supplier
              Flag Canada
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              MediPharm Labs Continues to Lead with Innovation - Launches CBG and Water-Soluble Products

              Details:

              Naturally derived oil and inhalable cannabigerol (cannabinoid) products added to MediPharm's wellness portfolio – the benefits of CBG without the effects of THC.

              Lead Product(s): Cannabidiol,Cannabigerol

              Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

              Highest Development Status: Approved Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable April 05, 2022

              Medipharm CB

              ICRI Spring Convention

              Not Confirmed

              envelop Contact Supplier

              MediPharm Labs

              Contact Supplier
              • Development Update
              Virtual BoothMedipharm is a full-service pharmaceutical company delivering high-quality, innovative Cannabis concentrate-based products & services.
              Contact Supplier Contact Supplier
              Flag Canada
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Insomnia Treatment Study using MediPharm Labs CBD50 Product to Proceed to Phase 2 with Health Canada Consent

              Details:

              McMaster University researchers using MediPharm Labs’ CBD50 formula and CBD:THC 10:2 formulation, which has the same as MediPharm Labs’ CBD25, have received a No Objection Letter from Health Canada to begin recruiting human subjects for a placebo-controlled trial.

              Lead Product(s): Cannabidiol

              Therapeutic Area: Sleep Product Name: CBD50

              Highest Development Status: Phase II Product Type: Small molecule

              Partner/Sponsor/Collaborator: McMaster University

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable August 31, 2021

              Medipharm CB

              ICRI Spring Convention

              Not Confirmed

              envelop Contact Supplier
              Medipharm VB RM
              Send me more info on How To Grow My Business Digitally?
              Post Enquiry
              POST ENQUIRY